Multiple Myeloma | Specialty

Novel CAR T-Cell Approaches Emerging in Multiple Myeloma

July 25th 2019

Deepu Madduri, MD, discusses ongoing trials examining CAR T-cell therapy in myeloma and the potential to use it in earlier lines of therapy.

Dr. Nadeem on Individualizing Therapy in Multiple Myeloma

July 25th 2019

Omar Nadeem, MD, a physician at Dana-Farber Cancer Institute and an instructor in medicine at Harvard Medical School, discusses individualizing therapy for patients with multiple myeloma.

Isatuximab Triplet Highly Active in Relapsed/Refractory Myeloma

July 24th 2019

Paul G. Richardson, MD, reviews the results of the phase III ICARIA-MM trial as well as preliminary data regarding melflufen in relapsed/refractory multiple myeloma.

Dr. Richardson Discusses New Directions in Multiple Myeloma

July 24th 2019

Paul G. Richardson, MD, clinical program leader and director of clinical research, Jerome Lipper Multiple Myeloma Center, and institute physician, Dana-Farber Cancer Institute, discusses new directions in multiple myeloma.

Dr. Raje Highlights Treatment Options for Relapsed Multiple Myeloma

July 18th 2019

Noopur S. Raje, MD, director, Center for Multiple Myeloma, Massachusetts General Hospital Cancer Center, and professor of medicine, Harvard Medical School, highlights the different options available for patients with relapsed multiple myeloma.

Dr. Cowan on Patient Eligibility Criteria for Transplant in Multiple Myeloma

July 17th 2019

Andrew J. Cowan, MD, an assistant professor of medicine at University of Washington School of Medicine and hematologist/oncologist at Seattle Cancer Care Alliance, discusses patient eligibility criteria for transplant in multiple myeloma.

Dr. Gasparetto on Safety Concerns With Venetoclax in Multiple Myeloma

July 17th 2019

Cristina Gasparetto, MD, an associate professor of medicine and director, Multiple Myeloma Program at Duke Cancer Institute, discusses safety concerns with venetoclax (Venclexta) in multiple myeloma.

FDA Approval Sought for Subcutaneous Daratumumab in Multiple Myeloma

July 12th 2019

A supplemental biologics license application has been submitted to the FDA for a new subcutaneous formulation of daratumumab (Darzalex) for the treatment of patients with multiple myeloma.

Dr. Biran on New Agents and Combos in Relapsed Multiple Myeloma

July 11th 2019

Noa Biran, MD, discusses new agents and combinations being studied for relapsed multiple myeloma.

Rethinking Treatment Schemas in Relapsed/Refractory Multiple Myeloma

July 11th 2019

Mounzer E. Agha, MD, discusses the approaches that are leading to prolonged survival in patients with relapsed/refractory multiple myeloma.

FDA Reviewing Isatuximab for Multiple Myeloma

July 10th 2019

The FDA has accepted an application for isatuximab for the treatment of patients with relapsed/refractory multiple myeloma.

Dr. Raptis on DRd in Newly Diagnosed Multiple Myeloma

July 10th 2019

Anastasios Raptis, MD, a clinical assistant professor of medicine at the University of Pittsburgh School of Medicine Hillman Cancer Center, discusses the use of daratumumab (Darzalex), lenalidomide (Revlimid), and dexamethasone (DRd) in the treatment of patients with newly diagnosed multiple myeloma.

Frontline Daratumumab/VRd Regimen Improves sCR Rate in Transplant-Eligible Myeloma

July 9th 2019

The quadruplet regimen of daratumumab, lenalidomide, bortezomib, and dexamethasone elicited a higher stringent complete response rate compared with lenalidomide, bortezomib, and dexamethasone alone in patients with transplant-eligible, newly diagnosed multiple myeloma, meeting the primary endpoint of the phase II GRIFFIN study.

Frontline Combos Significantly Improve Outcomes in Multiple Myeloma

July 8th 2019

Anastasios Raptis, MD, highlights promising combinations under investigation in the frontline setting and remaining challenges in multiple myeloma.

Dr. Cowan on Treatment Strategies in Transplant Eligible- and -Ineligible Myeloma

July 4th 2019

Andrew J. Cowan, MD, an assistant professor of medicine at University of Washington School of Medicine and hematologist/oncologist at Seattle Cancer Care Alliance, discusses treatment strategies for patients with transplant-eligible and -ineligible multiple myeloma.

Dr. Richardson Discusses the FDA Approval of Selinexor in Myeloma

July 3rd 2019

Paul Richardson, MD, clinical program leader, director of clinical research, Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute, RJ Corman Professor of Medicine, Harvard Medical School, discusses the FDA approval of selinexor in multiple myeloma.

Cowan Highlights Practice-Changing Combo Regimens in Multiple Myeloma

July 3rd 2019

Andrew J. Cowan, MD, discussed pivotal trials in multiple myeloma and potential for new treatments in the future.

Dimopoulos Highlights Benefit of Elotuzumab Triplet in Relapsed/Refractory Myeloma

July 2nd 2019

Meletios A. Dimopoulos, MD, discusses where the triplet combination of elotuzumab (Empliciti), pomalidomide (Pomalyst), and low-dose dexamethasone fits into the treatment paradigm of relapsed/refractory multiple myeloma and shared unanswered questions that remain in the space.

FDA Approves Frontline Daratumumab/Rd in Transplant-Ineligible Myeloma

June 28th 2019

The FDA has approved the combination of daratumumab with lenalidomide and dexamethasone for the treatment of patients with newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplantation.

Improving the Future Management of Multiple Myeloma

June 26th 2019